Separately, StockNews.com initiated coverage on shares of Pulse Biosciences in a research report on Saturday, September 17th. They issued a sell rating for the company.
Pulse Biosciences Stock Up 7.2 %
Shares of NASDAQ:PLSE opened at $1.49 on Wednesday. Pulse Biosciences has a fifty-two week low of $1.18 and a fifty-two week high of $24.58. The firm has a 50-day simple moving average of $1.58 and a 200 day simple moving average of $2.48. The company has a market cap of $55.32 million, a PE ratio of -0.74 and a beta of 1.97.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the stock. GSA Capital Partners LLP bought a new position in shares of Pulse Biosciences in the fourth quarter valued at approximately $164,000. Advisor Group Holdings Inc. boosted its holdings in shares of Pulse Biosciences by 25.5% in the first quarter. Advisor Group Holdings Inc. now owns 25,878 shares of the company’s stock valued at $126,000 after acquiring an additional 5,265 shares in the last quarter. TIAA FSB bought a new position in shares of Pulse Biosciences in the second quarter valued at approximately $42,000. Occudo Quantitative Strategies LP boosted its holdings in shares of Pulse Biosciences by 217.3% in the second quarter. Occudo Quantitative Strategies LP now owns 58,383 shares of the company’s stock valued at $54,000 after acquiring an additional 39,981 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new position in shares of Pulse Biosciences in the first quarter valued at approximately $378,000. 8.34% of the stock is currently owned by institutional investors.
About Pulse Biosciences
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
- Get a free copy of the StockNews.com research report on Pulse Biosciences (PLSE)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- General Mills: Superior Returns With Less Volatility
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.